Our mission at the UMC Utrecht Brain Center is to expand our comprehension of neuromuscular disorders through rigorous research.
Our mission at the UMC Utrecht Brain Center is to expand our comprehension of neuromuscular disorders through rigorous research. We aim to elucidate the intricate dynamics between genetic predispositions and environmental influences that contribute to these conditions. The UMC Utrecht is the national center of expertise for neuromuscular disorders and is part of the European Reference Network EURO-NMD.
In our Neuromuscular Disorders research team, we we tackle complex challenges. By fostering a collaborative environment with our patients, we are dedicated to deciphering the underlying mechanisms of these disorders. Our goal is to swiftly transition from understanding to therapeutic innovation. This commitment is underpinned by a synergistic collaboration between clinical and preclinical researchers, ensuring the integration of theoretical insights and practical applications.
Website European Reference Netwerk EURO-NMDAt the UMC Utrecht Brain Center, genetic research aims to understand the mutations that increase the risk of ALS, PSMA, and PLS. By exploring the genetic and environmental factors involved, researchers hope to identify potential treatments. Individuals can contribute to the NMZ Biobank, aiding in the collection of comprehensive genetic data. Key research areas include gene-environment interactions, the genetic differences in identical twins, oligogenetics, and large-scale projects like Project MinE, which uses advanced genomic techniques to uncover genetic causes and inform new treatments.
Read Part 3 Exciting times in ALS research: genetic researchUMC Utrecht is designated as a distinguished center of expertise for neuromuscular disorders. This recognition underscores our excellence and commitment to advancing the field and improving patient outcomes. We specialize in a broad spectrum of neuromuscular conditions, including amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and polyneuropathy. Our team is at the forefront of developing innovative treatments and advancing knowledge in these critical areas of medical research.
Discover our research groupsRelated
